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ABSTRACT
Targeted radiotherapy of metastatic neuroblastoma using the somatostatin 
receptor (SSTR)-targeted octreotide analogue DOTATATE radiolabelled with 
lutetium-177 (177Lu-DOTATATE) is a promising strategy. This study evaluates whether 
its effectiveness may be enhanced by combination with radiosensitising drugs. The 
growth rate of multicellular tumour spheroids, derived from the neuroblastoma cell 
lines SK-N-BE(2c), CHLA-15 and CHLA-20, was evaluated following treatment with 
177Lu-DOTATATE, nutlin-3 and topotecan alone or in combination. Immunoblotting, 
immunostaining and flow cytometric analyses were used to determine activation of 
p53 signalling and cell death. Exposure to 177Lu-DOTATATE resulted in a significant 
growth delay in CHLA-15 and CHLA-20 spheroids, but not in SK-N-BE(2c) spheroids. 
Nutlin-3 enhanced the spheroid growth delay induced by topotecan in CHLA-15 and 
CHLA-20 spheroids, but not in SK-N-BE(2c) spheroids. Importantly, the combination of 
nutlin-3 with topotecan enhanced the spheroid growth delay induced by X-irradiation 
or by exposure to 177Lu-DOTATATE. The efficacy of the combination treatments 
was p53-dependent. These results indicate that targeted radiotherapy of high risk 
neuroblastoma with 177Lu-DOTATATE may be improved by combination with the 
radiosensitising drugs nutlin-3 and topotecan.
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INTRODUCTION
Neuroblastoma is a malignancy predominantly 
of infancy and young children. It originates most 
commonly in the adrenal glands [1] and affects about 
one hundred individuals per year in the UK (http://www.
cancerresearchuk.org). About half of neuroblastomas 
are highly aggressive, as indicated by dissemination in 
children over one year of age or by adverse biological 
features such as amplification of the MYCN oncogene 
and by unresponsiveness to induction therapy or early 
relapse if a response is achieved. These high-risk 
neuroblastomas are responsible for 15% of paediatric 
cancer fatalities and new treatments are urgently needed 
[1]. Ninety percent of neuroblastoma tumours express the 
noradrenaline transporter (NAT). These can be treated with 
molecular radiotherapy using the iodine-131-radiolabelled 
noradrenaline analogue meta-iodobenzylguanidine 
(131I-mIBG) [2]. Targeted radiotherapy of neuroblastoma 
using 131I-mIBG has produced encouraging long-
term remission and palliation [3]. However, not all 
neuroblastoma tumours express NAT and resistance to 
131I-mIBG therapy may occur [3]. This has encouraged 
the consideration of alternative radiopharmaceuticals for 
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the targeted treatment of neuroblastoma. Somatostatin 
receptors (SSTRs) are overexpressed in human 
neuroblastomas [4–6] and the lutetium-177-radiolabelled 
somatostatin analogue DOTATATE (177Lu-DOTATATE) 
binds with high affinity to SSTRs, particularly subtype 
2 (SSTR2). The efficacy and safety of 177Lu-DOTATATE 
therapy in neuroendocrine tumours have been reviewed 
elsewhere [7]. Its therapeutic application in neuroblastoma 
is appropriate particularly for patients whose tumours 
demonstrate good uptake of 68Ga-DOTATATE on PET/CT 
imaging, who do not have a positive 123I-mIBG diagnostic 
scan or whose tumours are unresponsive to, or relapse 
after, 131I-mIBG therapy.
The safe and successful treatment of children with 
neuroblastoma using 177Lu-DOTATATE was recently 
reported [8, 9]. However, it is expected that maximal 
therapeutic potency of targeted radiotherapy will be 
derived from its combination with radiosensitisers 
[10, 11]. We previously showed that the topoisomerase 
I inhibitor topotecan enhanced 131I-mIBG efficacy in 
preclinical models [12]. Based on this study, the feasibility 
and tolerability of 131I-mIBG treatment in combination 
with topotecan were evaluated in children with metastatic 
neuroblastoma [13] and, subsequently, a prospective 
phase II study reported an overall response rate of 57% 
[14]. Finally, the multicentre randomised SIOPEN 
study EudraCT N° 2015-003130-27 will compare the 
effectiveness of 131I-mIBG in combination with topotecan 
to that of high dose thiotepa.
An alternative radiosensitising strategy is indicated 
by consideration of the role played by p53 in the response 
of neuroblastoma tumours to cytotoxic therapy. In 
neuroblastoma, the impairment of p53 signalling is seldom 
caused by inactivating mutations of the p53 gene [15, 16] 
but is more commonly due to upstream aberrations such 
as amplification of the p53 negative regulator MDM2 
and inactivation of the MDM2 inhibitor p14(ARF) [17]. 
Genetic studies have indicated that the restoration of 
p53 activity has promising therapeutic potential [18, 19], 
notably through induction of apoptosis and senescence in 
tumour cells [20, 21]. For instance, the cis-imidazoline 
small molecule nutlin-3 binds to the p53-binding pocket 
of MDM2, stabilises p53 and reduces tumour cell viability 
[22]. It has also been shown to enhance the efficacy of 
targeted radiotherapy [23] and to sensitise tumour cells 
to radiation treatment via p53-mediated apoptosis [24] 
or senescence [25]. Interestingly, it has been reported 
that resistance of tumour cells to the cytotoxicity of p53 
restoration could be overcome by radiation treatment 
[26]. Finally, the activation of the HIPK2 and p53 axis 
by nutlin-3 specifically in MYCN-amplified tumours 
sensitises tumours to apoptosis [27], thereby supporting 
that the strategy consisting of reactivating p53 in 
combination with radiotherapy is suitable for the treatment 
of patients with high risk neuroblastoma.
Topotecan has been shown to induce p53 expression 
[28, 29] and to synergise with MDM2 inhibitors in vitro 
and in vivo [30, 31]. It has also been suggested that nutlin-3 
may enhance the efficacy of chemotherapy [32, 33], notably 
through inhibition of multi-drug resistance protein 1 
function [34]. Therefore, while others have demonstrated 
the benefit to be derived by the combination of nutlin-3 
and topotecan, we hypothesised that this combination may 
sensitise neuroblastoma cells to 177Lu-DOTATATE targeted 
radiotherapy in a manner analogous to that of topotecan 
blended with 131I-mIBG treatment [12].
The aims of this study were first to characterise 
neuroblastoma cell lines with respect to their sensitivity 
to X-irradiation and 177Lu-DOTATATE as well as their 
ability to activate p53 signalling following treatment 
with nutlin-3, topotecan or X-irradiation; and second to 
assess whether the combination treatment consisting of 
topotecan and nutlin-3 sensitised neuroblastoma cells to 
X-irradiation and 177Lu-DOTATATE treatment and the 
relationship with activation of p53 signalling.
RESULTS
Characterisation of the sensitivity of SK-N-
BE(2c), CHLA-15 and CHLA-20 spheroids to 
177Lu-DOTATATE treatment
Uptake assays were performed in monolayers of 
various cell lines to determine their ability to concentrate 
177Lu-DOTATATE intracellularly. The competitive 
inhibitor of binding to SSTR, octreotide, was used to 
determine whether binding of 177Lu-DOTATATE to 
SSTR was required for intracellular transport. There was 
significantly greater 177Lu-DOTATATE internalisation 
by SK-N-BE(2c) (P < 0.001), CHLA-15 (P < 0.05) and 
CHLA-20 (P < 0.05) cells following exposure to 177Lu-
DOTATATE compared with exposure to 177Lu-DOTATATE 
in the presence of 1 µM octreotide (Figure 1A). In 
contrast, UVW, PC12, SK-N-SH, SH-SY5Y and CHLA-
90 cells did not internalise 177Lu-DOTATATE (Figure 1A). 
Furthermore, there was a statistically significant, time-
dependent, accumulation of 177Lu-DOTATATE by SK-N-
BE(2c) (P < 0.001), CHLA-15 (P < 0.01) and CHLA-20 
cells (P < 0.05), but not by UVW cells (Figure 1B). This 
observation is consistent with the expression of SSTR2 
by SK-N-BE(2c), CHLA-15 and CHLA-20 cells, but 
not by UVW cells (Figure 1C). Immunoblotting analysis 
of SSTR2 revealed variation in the apparent molecular 
size of SSTR2, as indicated by a broad band (Figure 1C). 
This has been hypothesised previously to be due to post-
translational modifications [35, 36]. Finally, a growth 
delay mediated by 8 h exposure to 177Lu-DOTATATE 
was indicated by a 1.2-fold (not significant), 1.9-fold 
(P < 0.05) and 1.5-fold (P < 0.01) decrease in AUC values 
in spheroids derived from SK-N-BE(2c), CHLA-15 and 
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CHLA-20 cells, respectively (Figure 1D, Supplementary 
Figure 1A), suggesting that SK-N-BE(2c) spheroids 
were more resistant to 177Lu-DOTATATE than CHLA-
15 and CHLA-20 spheroids. This may be explained by 
their relative radiosensitivity. Indeed, SK-N-BE(2c) 
spheroids were significantly more resistant to 4 or 6 
Gy X-irradiation than either CHLA-15 or CHLA-20 
spheroids (Figure 1E, Supplementary Figure 1B). 
Moreover, the fold change in AUC in response to 177Lu-
DOTATATE treatment correlated with that obtained 
in response to X-irradiation (r = 0.347, adj R2 = 0.61, 
P = 0.008) (Figure 1F). Together, these results indicated 
that SK-N-BE(2c), CHLA-15 and CHLA-20 spheroids 
were suitable in vitro experimental models to assess 
SSTR2-targeted therapy. Furthermore, the sensitivity 
of spheroids to 177Lu-DOTATATE correlated with 
radiosensitivity, indicating that radiosensitisers may 
enhance the efficacy of 177Lu-DOTATATE treatment.
Figure 1: The effect of exposure of SSTR2-expressing cells to 177Lu-DOTATATE on its intracellular accumulation and 
spheroid growth delay. (A) SSTR-mediated uptake of 177Lu-DOTATATE by various cell lines was measured after 4 h incubation with 
100 KBq/ml 177Lu-DOTATATE in the presence or in the absence of 1 µM octreotide. Data are means ± SEM, n = 3. Paired-samples t-tests 
were performed to determine the significance of the reduction in uptake by octreotide. (B) The cytosolic accumulation of 177Lu-DOTATATE 
was measured over 8 h following treatment with 100 kBq/ml 177Lu-DOTATATE. Data are means ± SEM, n = 3. Bonferroni-corrected one-
way ANOVA was performed. P-values indicate the significance of the difference between the mean uptake values at 8 h of SK-N-BE(2c), 
CHLA-15 and CHLA-20 cells in comparison with that of UVW cells. (C) The expression of SSTR2 was evaluated by immunoblotting 
in SK-N-BE(2c), CHLA-15 and CHLA-20 cells with UVW cells as negative control and β-actin as a loading control. (D) The spheroid 
growth delay induced by treatment of SK-N-BE(2c), CHLA-15 and CHLA-20 spheroids with 5 MBq/ml 177Lu-DOTATATE for 8 h is 
reported as a decrease in AUC values. The radioactivity concentration 5 MBq/ml was chosen based on preliminary experiments. Data are 
mean ± SEM, n = 3. One-way ANOVA with Bonferroni correction was performed. P-values indicate the significance of the difference in 
AUC values in comparison with that of untreated spheroids for each cell line. (E) The radiosensitivity of SK-N-BE(2c), CHLA-15 and 
CHLA-20 spheroids. Data are mean ± SEM, n = 3. One-way ANOVA with Bonferroni correction was performed. At each radiation dose, 
P-values indicate the significance of the difference in AUC values in comparison with that of SK-N-BE(2c) spheroids. (F) The AUC values 
of SK-N-BE(2c), CHLA-15 and CHLA-20 spheroids following treatment with 5 MBq/ml 177Lu-DOTATATE for 8 h correlated with AUC 
values obtained following treatment with 2 Gy X-irradiation. Data are mean ± SEM, n = 3. In all panels, one symbol indicates P < 0.05, 
two symbols indicate P < 0.01 and three symbols indicate P < 0.001.
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Characterisation of the sensitivity of SK-N-BE(2c), 
CHLA-15 and CHLA-20 cells to treatment with 
nutlin-3 and topotecan alone or in combination
In SK-N-BE(2c) cells, p53 expression was 
not increased in response to X-irradiation despite 
phosphorylation at serine 15 (Figure 2), a typical marker 
for p53 activation. The absence of p21Cip1/Waf1 (p21) 
expression indicated that the transcriptional activity of 
p53 was impaired at the p21 gene promoter in SK-N-
BE(2c) cells in response to X-irradiation (Figure 2). 
This conclusion is supported by the previously reported 
detection, in SK-N-BE(2c) cells, of mutations in the DNA-
binding domain of p53 [37]. In contrast, in CHLA-15 
and CHLA-20 cells, the increase in p53 expression in 
response to X-irradiation was associated with its activation 
by phosphorylation at serine 15 and expression of p21 
(Figure 2). This observation indicated that, in response 
to X-irradiation, p53 is an active transcription factor at 
the p21 gene promoter in CHLA-15 and CHLA-20 cells. 
Endogenous levels of p53 were higher in SK-N-BE(2c) 
cells than in CHLA-15 and CHLA-20 cells (Figure 2), 
perhaps reflecting a compensatory mechanism resulting 
from the impairment of p53 transcriptional activity.
Next, we determined the effect of exposure of SK-
N-BE(2c), CHLA-15 and CHLA-20 cells to nutlin-3 and 
topotecan on p53 expression and PARP cleavage, a marker 
of caspase activity which is a hallmark of apoptotic cell 
death. This analysis was carried out in cellular monolayers 
(Figure 3A) as well as in spheroids (Figure 3B). In 
SK-N-BE(2c) cells, combination treatment consisting of 
nutlin-3 with topotecan resulted in apoptotic cell death. 
This was probably due to topotecan alone since treatment 
with nutlin-3 as a single agent did not cause apoptosis 
(Figure 3A and 3B). In contrast, treatment of CHLA-15 
and CHLA-20 cells with nutlin-3 and topotecan alone 
or in combination resulted in increased p53 expression 
and PARP cleavage (Figure 3A and 3B). Furthermore, 
an increase in BAX expression was observed following 
treatment of CHLA-20 cells with nutlin-3 and topotecan 
alone or in combination (data not shown). Together, these 
results indicated that treatment with nutlin-3 induced 
p53 expression and apoptotic cell death in CHLA-15 and 
CHLA-20 cells which harbour transcriptionally active 
p53, whereas topotecan induced apoptotic cell death 
irrespective of the p53 status of SK-N-BE(2c), CHLA-15 
and CHLA-20 cells.
The effect of nutlin-3 and topotecan on cell cycle 
distribution was evaluated in SK-N-BE(2c), CHLA-15 and 
CHLA-20 cells grown as cellular monolayers (Figure 3C). 
The statistical analysis of the changes in the proportion of 
cells in Sub-G1, a measure of apoptosis induction, G0-G1, 
S and G2-M are summarised in Table 1. In SK-N-BE(2c) 
cells, nutlin-3 and topotecan alone or in combination did 
not cause a significant increase in sub-G1 population. This 
observation was contrasted by the significant increase in 
the sub-G1 population following nutlin-3 and topotecan 
alone or in combination in CHLA-15 and CHLA-20 cells 
(Figure 3C, Table 1). Topotecan caused a significant 
decrease in the proportion of cells in S and G2-M in 
CHLA-15 and CHLA-20 but not in SK-N-BE(2c) cells 
(Figure 3C, Table 1). The combination of nutlin-3 and 
topotecan induced, in CHLA-15 and CHLA-20 but not 
in SK-N-BE(2c) cells, a significant decrease in the G2-M 
population in comparison with the effect of nutlin-3 or 
topotecan as single agents (Figure 3C, Table 1). Together, 
these results indicated that, in the p53 functional cell lines 
CHLA-15 and CHLA-20, the depletion of cells in S and 
Figure 2: The effect of X-irradiation on p53 signalling in SK-N-BE(2c), CHLA-15 and CHLA-20 cells. The expression 
of p53 phosphorylated at serine 15 (p5315), total p53 and p21 in SK-N-BE(2c), CHLA-15 and CHLA-20 cells was evaluated by 
immunoblotting 1, 3 and 6 h following X-irradiation with 5 Gy. p5315 is a marker of p53 activation by upstream kinases, p21 is a marker 
of p53 transcriptional activity and β-actin is used as a loading control.
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G2-M phases of the cell cycle by treatment with nutlin-3 
and topotecan was probably due to apoptotic cell death in 
these particular phases of the cell cycle.
Finally, as spheroids grow, their heterogeneous 
internal morphology is characterised by a hypoxic, non-
dividing and dying core encircled by a proliferating outer 
layer [23]. The growth delay experiments were designed 
to treat the spheroids when they were 100 µm in diameter 
and to monitor them until they grew to a diameter of 
1 µm. The exposure of 100 µm diameter spheroids to the 
combination treatment consisting of nutlin-3 with topotecan 
resulted in a significantly increased growth delay in CHLA-
15 and CHLA-20 spheroids in comparison with single 
agent treatments (Figure 3D, Supplementary Figure 2). 
In contrast, there was no significant enhancement of 
topotecan-induced growth delay in SK-N-BE(2c) spheroids 
by combination with nutlin-3 (Figure 3D).
Together, these results suggested that the 
combination treatment consisting of nutlin-3 and 
topotecan may be more potent in tumours capable of 
activating p53 signalling. To evaluate this conjecture, we 
performed p53 gene expression knockdown in SH-SY5Y 
Figure 3: The effect of nutlin-3 and topotecan alone or in combination on the induction of p53 signalling, cell cycle 
arrest and spheroid growth delay. The expression of p53, full-length (FL) and cleaved (C) PARP was evaluated by immunoblotting 
6 h in monolayers (A) or 24 h in spheroids (B) following treatment of SK-N-BE(2c), CHLA-15 and CHLA-20 cells with nutlin-3 and 
topotecan alone or in combination. (C) The distribution of SK-N-BE(2c), CHLA-15 and CHLA-20 cells throughout the phases of the cell 
cycle was evaluated in monolayers by flow cytometry analysis of propidium iodide-stained cells following treatment for 12 h with nutlin-3 
and topotecan alone or in combination. (D) SK-N-BE(2c), CHLA-15 and CHLA-20 spheroids were treated with 10 µM nutlin-3 and 
10 µM topotecan alone or in combination for 24 h. The median AUC values resulting from each treatment were statistically compared with 
each other using Mann-Whitney pairwise comparisons. The symbol *indicates a comparison with untreated control, the symbol ¶indicates a 
comparison with nutlin-3 alone and the symbol †indicates a comparison with topotecan alone. One symbol indicates P < 0.05, two symbols 
indicate P < 0.01 and three symbols indicate P < 0.001. (E) Immunoblotting was used to determine the ability of p53-targeted siRNA 
(siRNAp53) or untargeted siRNA (siRNAunt) to abrogate the increase in p53 expression level following X-irradiation. SH-SY5Y cells were 
irradiated with 5 Gy and protein extracts harvested 3 h later. (F) SH-SY5Y cells exposed to either siRNAunt or siRNAp53 were exposed to 
200 nM nutlin-3 and 5 nM topotecan alone or in combination and the clonogenic cell kill was determined.
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cells followed by evaluation of the clonogenic cell kill 
induced by the combination of nutlin-3 and topotecan. We 
hypothesised that transfection of SK-N-BE(2c) cells with 
a p53-expressing vector would not result in a functional 
p53 axis due to the endogenous expression of mutant 
p53. In response to X-irradiation, there was an increase in 
p53 expression in SH-SY5Y cells exposed to untargeted 
siRNA but not in SH-SY5Y cells treated with p53-targeted 
siRNA (Figure 3E). In response to combination treatment 
consisting of nutlin-3 with topotecan, there was a 10-fold 
increase in clonogenic cell growth in p53-silenced SH-
SY5Y cells in comparison with SH-SY5Y cells exposed 
to untargeted siRNA (Figure 3F). This observation 
indicated that cytotoxicity resulting from the combination 
of nutlin-3 with topotecan depends on a functional p53 
signalling. In agreement, it has previously been reported 
that nutlin-3 and topotecan interact in a synergistic manner 
in cell lines with wild-type p53 [30, 31].
The sensitivity of tumours to cytotoxic treatment 
is known to depend on their size which influences 
drug penetration and resistance to treatment due to 
heterogeneous areas of quiescence and/or hypoxia [38]. 
Accordingly, we evaluated the effect of spheroid size on 
the cytotoxicity of nutlin-3 and topotecan. SK-N-BE(2c) 
and CHLA-20 spheroids were allowed to grow for 3 
weeks before exposure to nutlin-3 and topotecan as single 
agents. CHLA-15 spheroids were not recovered because 
of extensive disaggregation caused by the treatments. 
Similarly, combination treatments of SK-N-BE(2c) and 
CHLA-20 spheroids resulted in disaggregation and loss 
of spheroid morphology which precluded harvesting for 
immunohistochemistry. In CHLA-20, but not in SK-
N-BE(2c) spheroids, nutlin-3 and topotecan treatments 
increased expression of p53 and cleaved caspase 3, a 
marker of apoptotic cell death (Figure 4). In SK-N-BE(2c) 
spheroids, only topotecan treatment increased expression 
of cleaved caspase 3 (Figure 4). Importantly, caspase 3 
cleavage was observed throughout the spheroid, indicating 
that the phenomenon of drug resistance due to poor tissue 
penetration is unlikely in micrometastases. Furthermore, 
the induction, by nutlin-3 and topotecan, of apoptotic cell 
death throughout spheroids, suggested that, as well as 
targeted radiopharmaceuticals, nutlin-3 and topotecan are 
suitable treatment modalities for malignant lesions in the 
class size of micrometastases.
Enhancement of 177Lu-DOTATATE-induced 
spheroid growth delay by nutlin-3 and topotecan
Both topotecan and nutlin-3 have been shown to 
enhance targeted radiotherapy and to be radiosensitisers [12, 
23, 24]. Therefore we evaluated the effect of nutlin-3 and 
Table 1: Cell cycle analysis after treatment of cells with nutlin-3 and topotecan alone or in combination
SK-N-BE(2c)
Sub-G1 G0-G1 S G2-M
Control 3.68 ± 1.64 46.6 ± 0.93 22.1 ± 0.25 23.58 ± 0.74
10 µM nutlin-3 2.44 ± 0.75 44.8 ±1.10 15.6 ± 1.24* 32.2 ± 0.56***
10 µM topotecan 5.31 ± 0.98 58.6 ± 0.52* 20.6 ± 1.19 13.1 ± 0.50***
Nutlin-3 + toptecan 4.02 ± 0.17 58.5 ± 0.85¶¶¶ 21.0 ± 0.53¶¶ 14.2 ± 0.29¶¶¶
CHLA-15
Sub-G1 G0-G1 S G2-M
Control 3.16 ± 0.60 58.8 ± 3.67 14.3 ± 2.81 20.6 ± 1.13
10 µM nutlin-3 19.8 ± 1.70** 44.7 ± 3.65* 18.8 ± 5.34 14.6 ± 1.60***
10 µM topotecan 25.8 ± 12.2*** 58.2 ± 10.6 1.73 ± 0.33*** 12.8 ± 1.90***
Nutlin-3 + toptecan 33.1 ± 5.36¶ 56.9 ± 5.04¶ 3.35 ± 0.59¶¶¶ 4.57 ± 0.74¶¶¶†††
CHLA-20
Sub-G1 G0-G1 S G2-M
Control 1.73 ± 0.26 59.7 ± 0.76 15.6 ± 0.67 21.6 ± 0.84
10 µM nutlin-3 14.4 ± 1.23*** 56.5 ± 0.81 6.54 ± 0.53*** 21.9 ± 1.15
10 µM topotecan 18.8 ± 1.99*** 68.7 ± 1.78*** 2.78 ± 0.63*** 9.41 ± 0.51***
Nutlin-3 + toptecan 22.2 ± 1.40¶¶ 69.3 ± 1.05¶¶¶ 3.49 ± 0.65¶ 4.79 ± 0.20¶¶¶††
Propidium iodide-stained cells were analyzed using flow cytometry to determine cell cycle distribution 24 h following 
treatment of SK-N-BE(2c), CHLA-15 and CHLA-20 cells with 10 µM nutlin-3 and topotecan alone or in combination. 
One-way ANOVA with Bonferroni correction was performed. *, indicates a comparison with untreated control, ¶indicates 
a comparison with nutlin-3 alone, †indicates a comparison with topotecan alone. One symbol indicates P < 0.05, two 
symbols indicate P < 0.01 and three symbols indicate P < 0.001.
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topotecan alone or in combination on the spheroid growth 
delay induced by 177Lu-DOTATATE. The combination of 10 
µM of nutlin-3 and topotecan sterilised CHLA-15 spheroids 
(Figure 3D, Supplementary Figure 2). Consequently, 
in order to observe modulation of the spheroid growth 
delay by combination with 177Lu-DOTATATE, CHLA-
15 spheroids were also treated with an alternative, lower 
dosage of nutlin-3 and topotecan. Combined treatment 
with 5 µM nutlin-3 and 5 µM topotecan resulted in a 
significantly increased growth delay (P < 0.01) in CHLA-
15 spheroids in comparison with single agent treatments, 
without sterilisation (Supplementary Figure 3).
Firstly, we determined the spheroid growth delay 
resulting from treatment with nutlin-3 and topotecan alone 
Figure 4: The effect of nutlin-3 and topotecan on cellular proliferation, p53 expression and apoptotic cell death in 
SK-N-BE(2c) and CHLA-20 spheroids. The markers of histological organisation (haematoxylin and eosin, H&E), proliferation (Ki-
67), p53 expression and apoptotic cell death (cleaved caspase 3) were detected by immunohistochemistry in SK-N-BE(2c) and CHLA-20 
spheroids. The spheroids were allowed to grow for 3 weeks to reach 1 mm in diameter prior exposure to 10 µM nutlin-3 or 10 µM topotecan 
for 24 h. 
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or in combination with 177Lu-DOTATATE. Although not 
statistically significant, topotecan and the combination 
treatment consisting of nutlin-3 with topotecan enhanced 
the spheroid growth delay induced by 177Lu-DOTATATE 
(Figure 5A, Supplementary Figure 4A). Moreover, 
inhibition of proliferation was more prominent in CHLA-
15 and CHLA-20 spheroids, which harbour a functional 
p53 signalling pathway, than in SK-N-BE(2c) spheroids 
which do not (Figure 5A, Supplementary Figure 4A).
Secondly, the effect of nutlin-3 and topotecan alone 
or in combination on X-irradiation-induced spheroid growth 
delay was evaluated to determine whether radiosensitisation 
could explain the enhancement of 177Lu-DOTATATE 
efficacy. Similarly to the combination treatments with 
177Lu-DOTATATE, topotecan and the combination 
treatment consisting of nutlin-3 with topotecan enhanced 
the spheroid growth delay induced by X-irradiation 
although statistical significance was not reached (Figure 
5B, Supplementary Figure 4B). Furthermore, growth 
inhibition was more prominent in CHLA-15 and CHLA-
20 than in SK-N-BE(2c) spheroids. For instance, nutlin-3 
enhanced X-irradiation-induced spheroid growth delay to a 
greater extent in CHLA-20 spheroids than in SK-N-BE(2c) 
spheroids (Figure 5B). This observation was consistent with 
the enhanced increase in p53 and cleaved PARP expression 
following combination treatment consisting of nutlin-3 
and X-irradiation in comparison with nutlin-3 alone or 
X-irradiation alone in CHLA-20 cells but not in SK-N-
BE(2c) cells (Figure 5C). Similarly, the triple combination 
consisting of nutlin-3, topotecan and X-irradiation 
increased growth delay in CHLA-15 spheroids to a greater 
extent than in SK-N-BE(2c) spheroids (Figure 5B). PARP 
cleavage and p53 expression may already be maximal 
after treatment with topotecan and no further increase was 
possible following triple combination treatment consisting 
of nutlin-3, topotecan and X-irradiation (Figure 5C).
DISCUSSION
Multicellular tumour spheroids are well-established 
models of prevascular micrometastases that provide 
a means of studying the intratumoural distribution 
of therapeutic agents and of determining the effect 
of cytotoxic agents. They have previously been used 
extensively in targeted therapy research to investigate 
diffusion gradients of targeting agents, to assess efficacies 
of alternative modalities, to evaluate microdosimetry 
and to provide experimental model systems for testing 
hypotheses [11]. In this study, using multicellular tumour 
spheroids, we show that the radiosensitising combination 
consisting of nutlin-3 and topotecan enhanced the spheroid 
growth delay induced by 177Lu-DOTATATE. This effect 
was more prominent in spheroids composed of cells 
which harbour functional p53 signalling and constitutes an 
appropriate therapeutic option to target malignant lesions 
the size of micrometastases.
Due to the cytotoxic and cytostatic effects of 
somatostatin, the expression of SSTRs has been found 
to inversely correlate with MYCN amplification and 
to positively correlate with survival of patients with 
differentiated neuroblastomas [39–41]. However, these 
studies also found a subset of neuroblastoma tumours 
with MYCN amplification or classified as stage III-IV 
that were characterised by levels of SSTRs expression 
equivalent to tumours with a better prognosis [39–41]. 
Therefore, 177Lu-DOTATATE therapy is suitable for high 
risk neuroblastoma in a subset of patients with a positive 
68Ga-DOTATATE diagnostic scan.
We found that SSTR2 expression levels were 
greater in SK-N-BE(2c) than in CHLA-15 and CHLA-
20 cells (Figure 1C). This result was corroborated by the 
significant increased uptake of 177Lu-DOTATATE by SK-
N-BE(2c) cells than by CHLA-15 and CHLA-20 cells 
(Figure 1B). Although, it has recently been reported that 
SK-N-BE(2c) cells express lower levels of SSTR2 than 
CHLA-15 and CHLA-20 cells, this study did not report 
the outcome of a functional assay [42]. Furthermore, in 
our study, we observed that the spheroid growth delay 
induced by 177Lu-DOTATATE increased with increasing 
duration of exposure. This observation might be explained 
by the intracellular trafficking of SSTRs following 
agonist-induced internalisation [43]. For instance, it has 
been shown that SSTR2 is transported intracellularly 
and recycled back to the membrane within 1 h following 
octreotide stimulation [44]. The recycling of SSTR2 back 
to the membrane within 1h could allow the binding and 
internalisation of a second 177Lu-DOTATATE molecule. 
Thus, the longer the exposure to 177Lu-DOTATATE, the 
greater the internalised amount of 177Lu-DOTATATE. 
In conjunction with the prolonged retention of 177Lu-
DOTATATE within tumours [45], the time-dependent 
cytotoxicity of 177Lu-DOTATATE can be seen as a positive 
aspect of this therapy.
Recently, microtubule polymerisation has been 
suggested to be a target of topotecan, thereby challenging 
the opinion that topotecan’s cytotoxicity is due solely to 
topoisomerase I inhibition [46]. In our study, we found that 
10 µM topotecan as a single agent specifically killed cells 
in S and G2-M phases of the cell cycle (Table 1). However, 
it has been reported that this concentration may be too 
high to inhibit microtubule polymerisation [47]. Therefore, 
it is expected that the cellular depletion in the G2-M phase 
of the cell cycle is due to S phase-specific cell death rather 
than to interference with microtubule polymerisation 
during mitosis. Since S phase cells are radioresistant, 
radiosensitisation by topotecan may be explained by S 
phase-specific cell death. Furthermore, the combination 
of nutlin-3 with topotecan caused a significant decrease in 
the proportion of cells in G2-M (Table 1). The depletion 
of cells in S phase by topotecan alone and the depletion 
of cells in G2-M by the combination of nutlin-3 with 
topotecan were only significant in CHLA-15 and CHLA-
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20 cells - which are capable of activating p53 signalling 
- but not in SK-N-BE(2c) cells. This observation can be 
explained by the known roles of p53 in cell death and the 
activation of cell cycle checkpoints in S and G2 [47].
It has been shown that the p53 status of a tumour cell 
is a determinant of sensitivity to topotecan although this 
is subject to debate. For instance, it has been reported that 
p53 triggers the proteasomal degradation of topoisomerase 
I leading to resistance to topotecan [48] and that topotecan 
treatment is more potent in p53-deficient cells because of 
downregulation of XIAP and survivin [49]. In contrast, it 
has been suggested that the p53 status of glioma cell lines 
does not predict sensitivity to topotecan [50]. Importantly, 
in SK-N-BE(2c) spheroids, unable to activate p53 
signalling, treatment with nutlin-3 in combination with 
topotecan did not reverse the enhancement of spheroid 
growth delay induced by topotecan. This observation 
suggests that although the combination of MDM2 inhibitors 
and topotecan is likely to provide more benefit for patients 
whose tumours are p53 functional, this combination 
treatment may not result in a lower efficacy in patients 
with p53 non-functional tumours. Therefore, if MDM2 
inhibitors are found to be clinically safe, these molecules 
may be given in addition to topotecan regardless to the p53 
status of the patient’s tumour, thereby eliminating the need 
for the development of biomarkers of p53 signalling.
Figure 5: The effect of nutlin-3 and topotecan alone or in combination on the spheroid growth delay induced by 
X-irradiation or 177Lu-DOTATATE. (A) SK-N-BE(2c) and CHLA-20 spheroids were treated with 10 µM nutlin-3 (N) and 10 µM 
topotecan (T) for 24 h. CHLA-15 spheroids were treated with 5 µM nutlin-3 and 5 µM topotecan. 177Lu-DOTATATE (LuDO) treatment 
consisted of exposure for 8 h to 5 MBq/ml. The schedule of administrations of nutlin-3, topotecan and 177Lu-DOTATATE is shown below 
the histogram. (B) SK-N-BE(2c), CHLA-15 and CHLA-20 spheroids were pre-treated with nutlin-3 and topotecan alone or in combination 
for 24 h. The spheroids were irradiated (IR) with 3 Gy, 1 Gy and 3 Gy, respectively, at the start of exposure to nutlin-3 and topotecan. 
The schedule of administrations of nutlin-3, topotecan and IR is shown below the histogram. (C) The expression of p53, full-length (FL) 
and cleaved (C) PARP was evaluated by immunoblotting 6 h following treatment of SK-N-BE(2c), CHLA-15 and CHLA-20 monolayers 
with nutlin-3, topotecan and X-irradiation alone or in combination. (A, B) The median AUC values resulting from each treatment were 
statistically compared with each other using Mann–Whitney pairwise comparisons. However, statistical significance was not reached.
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The selection of patients who will most likely 
benefit from therapy is a major area of medical research. 
The levels of MDM2 expression have been reported 
to be prognostic and predictive biomarkers [51, 52]. 
Specifically, MDM2 expression or the presence of the 
MDM2 SNP309 polymorphism, which causes increased 
expression of the MDM2 gene, correlated negatively 
with outcome in patients with mesothelioma [53, 54]. 
Furthermore, MDM2 expression or the presence of the 
MDM2 SNP309 genetic variant correlated positively 
with sensitivity to chemotherapeutic agents including 
topoisomerase I inhibitors [53]. These studies suggest 
that MDM2 amplification and the MDM2 polymorphism 
SNP309 have prognostic value and may serve as predictive 
biomarkers of chemotherapy efficacy.
Recently, p53-independent MDM2 functions have 
been described with respect to possible adverse side-
effects in patients [54]. Specifically, MDM2 binds to the 
retinoblastoma tumour suppressor (Rb) and promotes its 
degradation [54]. Besides its tumour suppressor activity, 
Rb also regulates muscle development and myoblast 
proliferation and differentiation [54]. It has been shown 
that nutlin-3 treatment, which results in increased MDM2 
levels due to p53 activation, leads to Rb degradation 
and decreased levels of myoblast proliferation and 
differentiation markers, suggesting potential clinical 
complications [54]. However, the strategy consisting 
of reactivating p53 is currently being tested in various 
phase I clinical trials of cancer in order to assess safety 
and tolerability [55]. For instance, the inhibitor of the 
p53-MDM2 interaction, MK-8242, was investigated in 
47 patients with p53-wild-type solid tumours [56]. Its 
safety and tolerability at dosage producing clinical 
responses provided a rationale for further testing in a phase 
II clinical trial [56]. In another study, responses have been 
observed following administrations of MDM2 inhibitors 
with acceptable toxicity profiles [57]. Our present study, 
and others [30–33], suggest that the optimal use of nutlin-3 
may be in combination with alternative therapies. Since 
177Lu-DOTATATE concentrates in malignant lesions, the 
enhancement of chemotherapy efficacy by the combination 
with nutlin-3 only occurs in targeted cells, thus sparing 
normal tissues and reducing the gravity of adverse effects.
The goal of combination therapy is the potentiation 
of tumour-specific cytotoxicity at lower dosages of 
therapeutic agents while avoiding an increase in the risk 
of adverse effects in healthy tissues. The blending of 
drugs with non-overlapping mechanisms of action that 
function in concert to reactivate p53 may be a strategy to 
achieve this goal. Firstly, MDMX is structurally related 
to MDM2 and reduces p53 activity [18, 19]. The strategy 
consisting of dual inhibition of the p53-MDM2 and p53-
MDMX interactions has shown promise in pre-clinical 
testing [58]. Secondly, the p53 gene product Wip1/
PPM1D is a phosphatase which dephosphorylates and 
deactivates p53 [59]. The combination of nutlin-3 with 
Wip1 inhibition has been shown to be synergistic and to 
potently reactivate p53 signalling [60]. Interestingly, it has 
been shown that the novel Wip1 inhibitor GSK2830371 
reduced the growth of neuroblastoma xenografts in mice 
and enhanced the cytotoxicity caused by topoisomerase 
II inhibitors [61]. In the light of these observations, the 
radiosensitising properties of the nutlin-3 and topotecan 
combination may be safely enhanced further by dual 
inhibition of p53-MDM2 and p53-MDMX interactions or 
by inhibition of Wip1.
In summary, this study indicates that the efficacy 
of 177Lu-DOTATATE treatment of children with high risk 
neuroblastoma may be enhanced by the combination with 
the radiosensitising drugs nutlin-3 and topotecan. The 
precise dose-scheduling which will be optimal remains to 
be determined. Interestingly, it was recently reported that 
a single injection of 177Lu-DOTATATE in mice bearing 
CHLA-15 xenografts did not induce a significant long-
lasting growth delay [42], indicating that combination of 
177Lu-DOTATATE with radiosensitisers may be beneficial. 
Further experiments in animal models of neuroblastoma 
are therefore warranted to facilitate the clinical 
development of the combination of nutlin-3 and topotecan 
with 177Lu-DOTATATE. This strategy holds promise as 
another component in the multimodality arsenal for the 
treatment of children with high risk neuroblastoma.
MATERIALS AND METHODS
Cell culture
The neuroblastoma cell lines CHLA-90, CHLA-
15 and CHLA-20 were obtained from the Children’s 
Oncology Group and maintained in Iscove’s Modified 
Dulbecco’s medium supplemented with 2 mM 
L-glutamine, 1% (v/v) insulin, 1% (v/v) transferrin, 
1% (v/v) selenium and 20% (v/v) foetal bovine serum 
(FBS, Autogen Bioclear, UK) at 37° C in a 5% CO2 
atmosphere. The neuroblastoma cell lines SK-N-BE(2c), 
SK-N-SH and SH-SY-5Y and the phaeochromocytoma 
cell line PC12 were obtained from the American Tissue 
Culture Collection. SK-N-BE(2c) cells were maintained 
in Dulbecco’s Modified Eagle medium (DMEM) 
supplemented with 15% (v/v) FBS, 2 mM L-glutamine 
and 1% (v/v) non-essential amino acids at 37° C in a 5% 
CO2 atmosphere. PC12, SH-SY5Y and SK-N-SH cells 
were maintained in DMEM medium supplemented with 
10% (v/v) FBS and 2 mM L-glutamine at 37° C in a 5% 
CO2 atmosphere. The glioma cell line UVW was described 
previously [62]. UVW cells were maintained in Minimum 
Essential Medium supplemented with 10% (v/v) FBS and 
2 mM L-glutamine at 37° C in a 5% CO2 atmosphere. 
Unless otherwise stated, all reagents used for cell culture 
were purchased from ThermoFisher Scientific (UK).
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Silencing of p53 expression
The transfection of siRNAs was performed with 
Lullaby® siRNA transfection reagent according to the 
manufacturer’s protocol (OZ Biosciences, Marseille, 
France). The sense sequence of the p53-targeted siRNA 
was GAC UCC AGU GGU AAU CUA CUU Dharmacon 
(Lafayette, Colorado). The siGENOME non-targeting 
siRNA pool #2 from Dharmacon (Lafayette, Colorado) was 
used as a negative control. Following exposure to 124 nM 
siRNAs for 72 h, the cells were suspended by treatment 
with trypsin and seeded in triplicates at 2,000 cells 
per well in 6-well plates. Once attached, the cells were 
exposed to 200 nM nutlin-3 and 5 nM topotecan alone and 
in combination and incubated at 37° C in 5% CO2 to allow 
for colony formation. Once the colonies comprised more 
than 50 cells, the medium was removed and the colonies 
were fixed in 50% methanol (v/v) in PBS and stained with 
1% (v/v) crystal violet in PBS before counting.
177Lu-DOTATATE uptake assay
177Lu-DOTATATE was obtained from Advanced 
Accelerator Applications, France. The specific activity was 
37 GBq/mg. Cellular monolayers were incubated for 2, 4, 6 
and 8 h at 37° C in a 5% CO2 atmosphere in culture medium 
containing 100 kBq/ml 177Lu-DOTATATE in the presence 
or in the absence of 1 µM octreotide, a competitive inhibitor 
of binding to SSTR. The concentration of octreotide and 
the radioactivity concentration of 177Lu-DOTATATE were 
selected based on our preliminary investigation (data not 
shown). They were then washed three times in PBS. The 
radioactivity retained in the cells was extracted with 10% 
(w/v) trichloroacetic acid and measured using a γ-counter 
(Canberra Packard, UK). The number of cells was counted 
using a haemocytometer in a separate identical culture and 
177Lu-DOTATATE uptake was expressed as counts per 
minute (cpm) per cell.
Spheroid initiation
Spheroids were obtained using the liquid overlay 
technique [63]. Cellular monolayers were trypsinised and 
reseeded at a cellular density of 160,000 cells.cm-2 in ultra-
low attachment flasks (Corning, Netherlands). Spheroids 
formed within 2 days.
Treatment of spheroids and growth curve analysis
In order to assess the efficacy of radiopharmaceuticals 
combined with radiosensitisers, we selected the spheroid 
growth delay. A three-dimensional culture system is 
required to adequately represent therapeutic effects upon 
micrometastases (a major aim of targeted radionuclides) 
and because radionuclides are toxic to tumours not 
only because their decay particles inflict damage in 
targeted cells but also because cross-fire irradiation to 
neighbouring, untargeted cells contributes significantly 
to efficacy. Finally, spheroid growth was monitored 
for 21 days - a period long enough to observe at least a 
100-fold increase in volume. Twenty-one days is similar 
to the time period required for the formation of colonies 
in clonogenic assay. Single agent treatments consisted of 
exposure of the spheroids to 177Lu-DOTATATE for 8 h or 
to nutlin-3 and topotecan for 24 h. Combination treatments 
consisted of exposure of the spheroids to nutlin-3 and/
or topotecan for 16 h followed by exposure to nutlin-3 
and/or topotecan in combination with 177Lu-DOTATATE 
for 8 h. At the end of treatments, the spheroids were 
washed three times in PBS. Then, those of approximately 
100 µm in diameter were manually selected and 
individually transferred into ultra-low attachment plates 
for monitoring (Corning, Netherlands). For every spheroid, 
two orthogonal diameters, dmax and dmin, were measured 
twice per week using the image analysis software ImageJ 
(National Institute of Health, Bethesda, MD, USA) 
and the volume, V, was calculated using: V = π × dmax 
× dmin²/6,000,000 [64]. The spheroid volume, at various 
time points after the initiation of treatment, was computed 
as the quotient of volume at time t divided by volume 
at time zero (V/V0). In order to evaluate the effect of 
treatment over the course of an experiment, the area under 
the log V/V0 versus time curve (AUC) was calculated for 
individual spheroids using trapezoidal approximation. 
Spheroid growth delay caused by a treatment was indicated 
by a reduction of the AUC value in comparison with that of 
the untreated spheroids.
X-ray irradiation
Monolayers or spheroids were irradiated using an 
RS225 irradiator (Xstrahl, UK) at room temperature with 
195 kV/10 mA X-rays producing a dose rate of 1.64 Gy/min 
at a distance of 30 cm.
Statistical analysis of spheroid growth delay
The distribution of AUC values was not normal, 
as indicated by the Shapiro–Wilk test. Therefore, non-
parametric Kruskal–Wallis testing was used to determine 
whether experimental data indicated a significant level 
of difference between the medians of the groups. If the 
P-value corresponding to the Kruskal–Wallis test was 
less than 0.05, the Mann–Whitney test was used for 
pairwise comparisons. The comparison of single agent 
treatment with combination treatment was characterised 
by the following features. Firstly, in order to demonstrate 
enhancement of 177Lu-DOTATATE-induced spheroid 
growth delay, the observed effect in response to 
combination treatment of a radiosensitiser with 177Lu-
DOTATATE had to be greater than that induced by 177Lu-
DOTATATE or the radiosensitiser alone. Secondly, an 
absence of enhancement of 177Lu-DOTATATE-induced 
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growth delay could be due to insufficient radiosensitiser 
dosage. Therefore, the evaluation of the modification of 
the effect of 177Lu-DOTATATE involved a family of four 
pairwise comparisons: radiosensitiser versus untreated 
control, 177Lu-DOTATATE versus untreated control, 
radiosensitiser + 177Lu-DOTATATE versus radiosensitiser 
and radiosensitiser + 177Lu-DOTATATE versus 177Lu-
DOTATATE. To compensate for multiple pairwise 
comparisons, Bonferroni correction was applied. In order 
to retain the criterion P < 0.05, the level of significance of 
each pairwise comparison was set to 0.0125.
Immunoblotting
Antibodies against SSTR2 and β-actin were 
obtained from Abcam, UK. The antibody against p53 
was obtained from Santa-Cruz, US. Antibodies against 
p53 phosphorylated at serine 15 and PARP were obtained 
from New England Biolabs, UK. The antibody against p21 
was obtained from BD Pharmingen, UK. Whole cellular 
protein extracts were resolved in reducing and denaturing 
conditions by sodium dodecyl sulphate polyacrylamide 
gel electrophoresis. Proteins were transferred on to 
polyvinylidene fluoride (PVDF) Immobilon-P membranes 
(Millipore, UK). Membranes were blocked with 7.5% 
(w/v) milk for 2 h prior to incubation with the primary 
antibodies overnight at 4° C. Membranes were then 
washed and incubated at room temperature for 1 h with 
horseradish peroxidase-conjugated secondary anti-
mouse (Cell Signalling, UK) or anti-rabbit antibody (Cell 
Signalling, UK) to enable chemiluminescent detection 
using ECL (ThermoFisher Scientific, UK).
Cell cycle analysis
SK-N-BE(2c), CHLA-15 and CHLA-20 cellular 
monolayers were exposed for 12 h to 10 µM nutlin-3 and 
10 µM topotecan alone or in combination. After 12 h, 
the cells were harvested by trypsinisation and fixed in 
70% (v/v) ethanol at −20° C. The cells were stained with 
10 µg/ml propidium iodide and 200 µg/ml RNAse A for at 
least 10 min prior to analysis using a FACSCalibur flow 
cytometry system (BD Biosciences, UK). Flow cytometric 
data were quantified using FlowJo 7.6.5 software.
Immunocytochemistry
After treatment, the spheroids were fixed in 10% 
neutral formalin (Cellpath, UK) for 24 h at 4° C. The 
spheroids were agitated and gently mixed before being 
carefully placed at the centre of biopsy paper (Leica, 
UK). The biopsy paper was then folded over twice and 
placed into the tissue processing cassette for processing 
through 70, 90, 95% (v/v) alcohol, 100% (v/v) ethanol, 
xylene and molten wax. The solid wax that may have 
formed was removed by placing the unfolded biopsy 
paper containing the spheroids onto a hot plate. Using 
heated forceps, the spheroids were then transferred from 
the biopsy paper into a tissue embedding mold containing 
molten wax. A tissue cassette was finally placed onto the 
embedding mold and left to harden. Once hardened, the 
paraffin wax block was removed and 4 µm sections were 
obtained using a Finesse microtome (ThermoFischer, 
UK). Spheroid sections were de-waxed in xylene and 
re-hydrated by successive immersions in graded alcohol 
and tap water. Endogenous peroxidase activity was 
quenched using peroxidase-blocking solution (Dako, 
UK). Heat-induced antigen retrieval was performed in 
a 10 mM sodium citrate, 0.05% (v/v) Tween 20, pH6 
buffer at 98° C for 25 minutes using a pre-treatment 
module (Dako, UK). The sections were then washed 
using Tris-buffered Tween before being exposed to anti-
Ki67 (ThermoFisher Scientific, UK), anti-p53 (Leika, 
UK) or anti-cleaved caspase 3 (Cell Signalling, UK) 
antibodies. Species appropriate secondary antibodies 
(Dako EnVision, UK) were applied for 30 min followed 
by 3,3′-diaminobenzidine tetrahydrochloride for 10 min. 
The reaction was terminated with deionized water for 
1 min. The sections were then counterstained with Gills 
haematoxylin and the nuclei blued using Scott’s tap 
water. The sections were then dehydrated through graded 
alcohol, cleared in xylene and mounted with a glass 
coverslip using DPX mountant for microscopy.
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